{
    "id": 2805,
    "fullName": "MDM4 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MDM4 over exp indicates an over expression of the Mdm4 protein. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4194,
        "geneSymbol": "MDM4",
        "terms": [
            "MDM4",
            "HDMX",
            "MDMX",
            "MRP1"
        ]
    },
    "variant": "over exp",
    "createDate": "12/22/2014",
    "updateDate": "01/03/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5573,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with CTX-1 resulted in increased cell death of transformed fibroblasts with over expression of MDM4 (MDMX) in culture (PMID: 26883273).",
            "molecularProfile": {
                "id": 2638,
                "profileName": "MDM4 over exp"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5572,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CTX-1 induced cell death in an acute myeloid leukemia cell line with MDM4 (MDMX) over expression in culture (PMID: 26883273).",
            "molecularProfile": {
                "id": 2638,
                "profileName": "MDM4 over exp"
            },
            "therapy": {
                "id": 3899,
                "therapyName": "CTX-1",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5110,
                    "pubMedId": 26883273,
                    "title": "Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26883273"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14101,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ALRN-6924 induced apoptosis and inhibited growth of TP53 wild-type acute myeloid leukemia cell lines with elevated Mdm4 expression in culture (PMID: 29643228).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2273,
                "therapyName": "ALRN-6924",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11462,
                    "pubMedId": 29643228,
                    "title": "Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29643228"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7729,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 in combination with Zelboraf (vemurafenib) resulted in enhanced growth inhibition of TP53 wild-type melanoma cells over expressing MDM4 in culture (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 4554,
                "therapyName": "SAH-p53-8 + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1533,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAH-p53-8 treatment of TP53 wild-type melanoma cells over expressing MDM4 inhibited growth in culture and in xenograft models (PMID: 22820643).",
            "molecularProfile": {
                "id": 2644,
                "profileName": "MDM4 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 1836,
                "therapyName": "SAH-p53-8",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1453,
                    "pubMedId": 22820643,
                    "title": "MDM4 is a key therapeutic target in cutaneous melanoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22820643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2638,
            "profileName": "MDM4 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 4557,
                    "name": "MDM4 inhibitor",
                    "profileName": "MDM4 over exp"
                }
            ]
        },
        {
            "id": 2644,
            "profileName": "MDM4 over exp TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}